good "benchmark" or minimum bayes factor for differential expression?
I'm filtering a file with genome wide analysis of bayes factors between two stages in neuron development. What's a good minimum BF for a gene to be counted as differentially expressed? In a Nature Communications paper it seems that they used BF>20, but I'm not sure if that's just for the specific study they were doing, or if that's a generally universal value.
-
-
In general, Bayes Factors are a bit like interpreting a p-value and the choice of cutoff for "significance" is arbitrary. The Jeffrey's scale is one widely used suggested scaling of significance where K's >10 are "strong" inidcators of significant differences, and K's > 10^2 are "decisive" indicators of significance and anything in between as "very strong" indication (that is, that gene expression levels for population M2 are greater than those for population M1, for example).
In my experience, Bayes factors are not at all commonly used for differential gene expression, so you may need to convince an audience of the validity of the methods used to generate that file (not to mention explaining just what a Bayes factor is as most genomic biologists will have never heard of the term).Last edited by mbblack; 08-05-2015, 04:18 AM.Michael Black, Ph.D.
ScitoVation LLC. RTP, N.C.
-
Tumors contain complex mixtures of cell populations that evolve in response to treatment and host-specific factors. Tissue biopsies provide only static snapshots of a tumor’s state. But what if we could follow that evolution over time using a minimally invasive technique?
Liquid biopsies can detect tumor-derived material circulating in the bloodstream, providing a way to study treatment response, detect emerging resistance, and discover new biomarkers. Circulating...10-14-2026, 09:55 AM -
Researchers using sequencing and genomics tools often have to make trade-offs. They can choose between speed or scale, short reads or long-range information, or targeted panels or a view of the whole transcriptome. New technologies that have been released this year are built to address those tough choices.
We asked six companies the same four questions to learn about their latest products. The new technologies bring a lot to the table, including rethinking sequencing...
Comment